Alzheimer’s disease (AD), the most common form of dementia, is a progressive and irreversible neurodegenerative disorder. Structural MRI is widely used for diagnosis, revealing brain changes associated with AD. However, these alterations are often subtle and difficult to detect manually, particularly at early stages. Early intervention during prodromal stages, such as mild cognitive impairment (MCI), can help slow disease progression, highlighting the need for reliable automated methods. In this work, we introduce a dual-level evaluation framework comparing fifteen deep learning architectures, including convolutional neural networks (CNNs), Transformers, and hybrid models, for classifying AD, MCI, and cognitively normal (CN) subjects using the ADNI dataset. A central focus of our work is the impact of robust and standardized preprocessing pipelines, which we identified as a critical yet underexplored factor influencing model reliability. By evaluating performance at both slice-level and scan-level, we reveal that multi-slice aggregation affects architectures asymmetrically. By systematically optimizing preprocessing steps to reduce data variability and enhance feature consistency, we established preprocessing quality as an essential determinant of deep learning performance in neuroimaging. Experimental results show that CNNs and hybrid pre-trained models outperform Transformer-based models in both slice-level and scan-level classification. ConvNeXtV2-L achieved the best scan-level performance (91.07%), EfficientNetV2-L the highest slice-level accuracy (86.84%), and VGG19 balanced results (86.07%/88.52%). ConvNeXtV2-L and SwinV1-L exhibited scan-level improvements of 7.60% and 9.04% respectively, while EfficientNetV2-L experienced degradation of 2.66%, demonstrating that architectural selection and aggregation strategy are interdependent factors. These findings suggest that carefully designed preprocessing not only improves classification accuracy but may also serve as a foundation for more reproducible and interpretable Alzheimer’s disease detection pipelines.
Bricaud et al. (Thu,) studied this question.